Skip to main content

Table 2 Baseline scores across regions a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

  North America Western Europe Australia/South Africa Japan Asia Eastern Europe/Russia South America/Mexico Total sample
MMSE at screen, mean ± SD 21.0 ± 3.2SA,EE,AS 21.0 ± 3.1SA,EE,AS 21.0 ± 3.0SA,EE,AS 20.9 ± 2.9SA,EE,AS 19.8 ± 3.1JP,AU,WE,NA 20.1 ± 3.0JP,AU,WE,NA 20.2 ± 3.0JP,AU,WE,NA 20.8 ± 3.1
MMSE at baseline, mean ± SD 21.0 ± 3.7SA,EE,AS 20.9 ± 3.4SA,EE,AS 20.8 ± 3.4AS 20.9 ± 3.3AS 19.8 ± 3.4JP,AU,WE,NA 20.3 ± 3.1WE,NA 20.3 ± 3.1WE,NA 20.7 ± 3.5
ADAS-cog11, mean ± SD 22.0 ± 8.9SA,EE,AS,WE 23.4 ± 8.9SA,EE,JP,NA 21.9 ± 9.2SA,EE,AS 21.4 ± 6.7SA,EE,AS,WE 24.1 ± 7.9EE,JP,AU,NA 27.3 ± 10.7AS,JP,AU, WE,NA 25.0 ± 8.8JP,AU,WE,NA 23.1 ± 9.0
ADCS-ADL, mean ± SD 62.4 ± 11.7SA,EE,AS,JP,WE 59.3 ± 13.3SA,EE,NA 59.6 ± 13.3SA,EE 60.2 ± 11.4SA,EE,NA 56.5 ± 14.5SA,EE,NA 50.9 ± 15.7AS,JP, AU, WE,NA 53.3 ± 14.4AS,JP,AU, WE,NA 59.2 ± 13.5
CDR-SB, mean ± SD 5.1 ± 2.5SA,EE,AS 5.3 ± 2.6SA,EE,AS 5.5 ± 2.6SA,EE,AS 5.1 ± 2.8SA,EE 4.7 ± 2.6SA,EE,AU,WE,NA 7.0 ± 3.2AS,JP,AU, WE,NA 6.4 ± 2.9AS,JP,AU,WE,NA 5.4 ± 2.7
NPI, mean ± SD 9.2 ± 10.9SA,JP,AU, WE 10.5 ± 11.3AS,JP,NA 11.9 ± 12.1AS,JP,NA 6.6 ± 8.6SAEE,AU,WE,NA 7.7 ± 9.2SA,EE,AU,WE 10.7 ± 11.6AS,JP 11.9 ± 12.1AS,JP,NA 9.6 ± 11.0
  1. aSA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa; WE = P < 0.01 vs Western Europe; NA = P < 0.01 vs North America; ADAS-cog11 = 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale;; ADCS-ADL = Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory; CDR-SB = Clinical Dementia Rating scale Sum of Boxes; MMSE = Mini Mental State Examination.